Your shopping cart is currently empty

(E/Z)-SIB-1893 (SIB 1893) is the racemate of (E)-SIB-1893 and (Z)-SIB-1893. (E)-SIB-1893 is a selective, noncompetitive mGluR5 antagonist with anticonvulsant activity .

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $67 | In Stock | In Stock | |
| 10 mg | $118 | In Stock | In Stock | |
| 25 mg | $247 | In Stock | In Stock | |
| 50 mg | $392 | In Stock | In Stock | |
| 100 mg | $592 | In Stock | In Stock | |
| 500 mg | $1,280 | - | In Stock |
| Description | (E/Z)-SIB-1893 (SIB 1893) is the racemate of (E)-SIB-1893 and (Z)-SIB-1893. (E)-SIB-1893 is a selective, noncompetitive mGluR5 antagonist with anticonvulsant activity . |
| In vitro | We investigated the role of mGluR5 in acute NMDA and glutamate-mediated neurodegeneration in cultured rat cortical cells using the mGluR5 antagonists SIB-1893 (20 or 200 μM; rat cortical cells) and found that they provide significant protection.[4] |
| In vivo | (E/Z)-SIB-1893 (10, 20, and 30 mg/kg; i.p.; 0-180 min) considerably lowered the body temperature in animals at 90, 120, and 180 min after its systemic injection of 30 mg/kg. In contrast, the drug at 10 and 20 mg/kg remained without effect on the body temperature in rats. Based on our preclinical study, one can conclude that (E/Z)-SIB-1893 produces hypothermia in freely moving rats in a dose-dependent manner.[1] SIB 1893 (10 and 20 mg/kg; mice; i.p.) did not affect the protective action of valproate, ethosuximide, phenobarbital, and clonazepam in this test. The combined treatment of SIB 1893 with conventional antiepileptic drugs did not lead to motor impairment. Long-term memory disturbances were observed only in the case of the combination of SIB 1893 with phenobarbital.[2] |
| Synonyms | SIB 1893 |
| Molecular Weight | 195.26 |
| Formula | C14H13N |
| Cas No. | 6266-99-5 |
| Smiles | C(=CC1=CC=CC=C1)C=2N=C(C)C=CC2 |
| Relative Density. | 1.072g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 90 mg/mL (460.92 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Saline: 3.3 mg/mL (16.9 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.